EBAG9/RCAS1 expression and its prognostic significance in prostatic cancer
EBAG9/RCAS1 expression and its prognostic significance in prostatic cancer
复制标题
DOI：
10.1002/ijc.11205
复制
发表时间：
2003-09
影响因子：
6.4
通讯作者：
Satoru Takahashi;T. Urano;F. Tsuchiya;T. Fujimura;T. Kitamura;Y. Ouchi;M. Muramatsu;S. Inoue
中科院分区：
文献类型：
--
作者：
Satoru Takahashi;T. Urano;F. Tsuchiya;T. Fujimura;T. Kitamura;Y. Ouchi;M. Muramatsu;S. Inoue
雌激素受体结合片段相关基因9（EBAG 9）已被鉴定为来自MCF-7人乳腺癌细胞的主要雌激素应答基因（Watanabe T等人，Mol Cell Biol 1998;18：442-9）。EBAG 9与RCAS 1（在SiSo细胞上表达的受体结合癌抗原）相同，RCAS 1已被报道为涉及免疫逃逸的癌细胞表面抗原（Nakashima M等人，Nat Med 1999;5：938-42）。在本研究中，我们检测了EBAG 9在人前列腺组织中的表达，并研究了其在前列腺癌患者中的预后意义。通过蛋白质印迹分析测定正常前列腺上皮细胞和PC-3、DU 145和LNCaP癌细胞中的EBAG 9表达。对21例良性和81例恶性前列腺标本进行免疫组化分析，并对患者的临床、病理和生存数据进行回顾。与正常上皮细胞相比，EBAG 9在前列腺癌细胞中大量表达。在81例癌组织样本中的44例（54%）中发现了EBAG 9细胞质中的强和弥漫性免疫染色。EBAG 9表达与晚期病理分期和高Gleason评分显著相关（分别为p = 0.0305和< 0.0001）。与囊内原发性肿瘤（54%）相比，EBAG 9在囊穿透（79%）和淋巴结转移（100%）部位更频繁地表达（分别为p = 0.0264和0.0048）。EBAG 9阳性免疫反应性与PSA无失败生存率显著相关（p = 0.0059）。EBAG 9/RCAS 1可能通过免疫逃逸系统在癌症进展中发挥重要作用。EBAG 9/RCAS 1表达的免疫检测可作为前列腺癌患者的阴性预后指标。© 2003 Wiley利斯公司
Estrogen receptor‐binding fragment‐associated gene 9 (EBAG9) has been identified as a primary estrogen‐responsive gene from MCF‐7 human breast cancer cells (Watanabe T, et al., Mol Cell Biol 1998;18:442–9). EBAG9 is identical with RCAS1 (receptor‐binding cancer antigen expressed on SiSo cells), which has been reported as a cancer cell surface antigen implicated in immune escape ( Nakashima M, et al., Nat Med 1999;5:938–42). In our present study, we examined EBAG9 expression in human prostatic tissues and investigated its prognostic significance in patients with prostatic cancer. EBAG9 expression in normal prostatic epithelial cells and PC‐3, DU145 and LNCaP cancer cells was determined by Western blot analysis. Immunohistochemic analysis was performed in 21 benign and 81 malignant prostatic specimens, and patients' charts were reviewed for clinical, pathologic and survival data. EBAG9 was abundantly expressed in the prostate cancer cells compared to the normal epithelial cells. Strong and diffuse immunostaining in the cytoplasm of EBAG9 was found in 44 of 81 (54%) cancerous tissue samples. EBAG9 expression significantly correlated with advanced pathologic stages and high Gleason score (p = 0.0305 and < 0.0001, respectively). EBAG9 was more frequently expressed at sites of capsular penetration (79%) and lymph node metastasis (100%) compared to intracapsular primary tumors (54%) (p = 0.0264 and 0.0048, respectively). Positive EBAG9 immunoreactivity significantly correlated with poor PSA failure‐free survival (p = 0.0059). EBAG9/RCAS1 may play a significant role in cancer progression via an immune escape system. Immunodetection of EBAG9/RCAS1 expression can be a negative prognostic indicator for patients with prostatic cancer. © 2003 Wiley‐Liss, Inc.